alexa Treatment of Hepatitis C with First Generation Protease Inhibitors | OMICS International | Abstract
ISSN: 2167-1052

Advances in Pharmacoepidemiology and Drug Safety
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Treatment of Hepatitis C with First Generation Protease Inhibitors

Marcos Cardoso Rios*, Evelyne de Andrade Mota, Layana Tyara Sandes Fraga, Saulo Makerran Loureiro, Tereza Virgínia Silva Bezerra Nascimento, Ângelo Roberto Antoniolli, Divaldo Pereira de Lyra-Junior and Alex Franca

Universidade Federal de Sergipe, São Cristovão, Sergipe, Brazil

*Corresponding Author:
Marcos Cardoso Rios
Universidade Federal de Sergipe, São Cristovão, Sergipe, Brazil
Tel: +55 79 3432-8200
E-mail: [email protected]

Received Date: October 26, 2016; Accepted Date: December 26, 2016; Published Date: December 30, 2016

Citation: Rios MC, Mota EA, Fraga LTS, Loureiro SM, Nascimento TVSB, et al. (2016) Treatment of Hepatitis C with First Generation Protease Inhibitors. Adv Pharmacoepidemiol Drug Saf 5:214. doi: 10.4172/2167-1052.1000214

Copyright: © 2016 Rios MC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Recent changes in the treatment of hepatitis C have increased the demands for medical care and pharmacovigilance. The aim of this study was to evaluate the epidemiological profile, drug therapy, and response to treatment of chronic hepatitis C patients treated with interferon plus ribavirin in combination with Telaprevir (TVR) or Boceprevir (BOC), in an outpatient hospital in Northeast Brazil. A retrospective review of patient records archived at the Hepatology Unit of the University Hospital of the Federal University of Sergipe was conducted. A total of 48 treatments were analyzed, with TVR (35) being the most used antiviral drug. The overall Sustained Virologic Response (SVR) rate after a 48-week treatment course was 61.5% among patients who received TVR and 50% among patients who received BOC. However, the SVR rate was lower when intention-to-treat was considered, decreasing to 22.8% for TVR treatment, and 15.4% for BOC treatment. Cirrhosis was one of the main characteristics of patients with suspension of treatment due to adverse reactions associated with TVR use. During combination drug treatment, adverse reactions caused by the different drugs are cumulative, creating a scenario that is difficult to control. These findings indicate the need for multidisciplinary care, and for review of therapeutic indications or even evaluating the anticipation of treatment of chronic carriers of hepatitis C, in order to achieve better results. The availability of new direct antiviral drugs will negate the need for a therapy associated with significant adverse reactions and low therapeutic response.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version